Play Earnings CallPlay Earnings Call
Plus Therapeutics, Inc. (PSTV) Discusses Business Update, REYOBIQ Clinical Program Progress, and Recent Financial Offering January 22, 2026 9:00 AM EST
Company Participants
Marc Hedrick – President, CEO & Director
Andrew Sims – VP & CFO
Conference Call Participants
Vivian Cervantes
Jason Kolbert – D. Boral Capital LLC, Research Division
Xun Lee – H.C. Wainwright & Co, LLC, Research Division
Edward Woo – Ascendiant Capital Markets LLC, Research Division
Presentation
Operator
Good day, and welcome to the Plus Therapeutics January 22, 2026, Business Update Conference Call. [Operator Instructions] Please note that this event is being recorded.
I would now like to turn the conference over to Vivian Cervantes, CORE Investor Relations. Please go ahead.
Vivian Cervantes
Thank you, Chloe. Good morning, and thank you for participating in today’s conference call. Earlier this morning, the company released a business update and outline of progress in its REYOBIQ clinical program and CNSide U.S. commercialization. A copy of that press release can be found on the company’s website at plustherapeutics.com under the Investors tab.
In addition, the company’s latest corporate presentation was also filed with the SEC in an 8-K filing and posted in the IR section of the company’s website. Joining me on today’s call are Marc Hedrick, Chief Executive Officer; and Andrew Sims, Chief Financial Officer. During the call, management will be making forward-looking statements, including statements that address Plus Therapeutics’ expectations for future performance or operational results.
Forward-looking statements involve risks and other factors that may cause actual results to differ materially from those statements. For more information about these risks, please refer to the risk factors described in Plus Therapeutics’ most recently filed annual report on Form 8-K and subsequent periodic reports filed with the SEC and the press release that accompanies this call, particularly the cautionary statements within.
The
